Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis) MedDRA version: 22.1 Level: LLT Classification code 10052254 Term: Hepatic impairment System Organ Class: 100000004871
Conditions
Interventions
Product Name: GB1211
Product Code: GB1211
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: GB1211
Current Sponsor code: GB1211
Other descriptive name: GB1211
Concentration unit: mg milligram(s)
Sponsors
Galecto Biotech AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Males or females, of any race, = 18 and = 75 years of age at enrolment 2.Body mass index (BMI) of = 18–40 kg/m2 3.Participants with hepatic impairment: a.PART 1 and PART 2: Moderate hepatic impairment, as defined by the Child–Pugh score (Child-Pugh B) who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior and for the duration of this study. b.PART 3: Severe hepatic impairment as defined by the Child–Pugh score (Child Pugh C) who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior and for the duration of this study. 4.Healthy participants (controls) in PART 1 and PART 3: a.Healthy as determined by the investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac assessment b.Match at least one of the participants with moderate or severe hepatic impairment with respect to gender, age (±10 years), and body mass index (BMI) ± 15% (ensure every participant with hepatic impairment has at least 1 matched control.) 5.Women of non-childbearing potential defined as permanently sterile or postmenopausal 6.Males will agree to use contraception throughout the study and until 90-days after the Follow-up visit 7.Male participants must agree to refrain from sperm donation from the date of Randomisation (Day 1) until 90 days after the Follow up visit 8.At screening, and baseline, vital signs which are within the following ranges: • Systolic blood pressure: = 90 and = 150 mm Hg • Diastolic blood pressure: = 50 and = 95 mm Hg • Pulse rate: = 40 and = 100 Beats Per Minute (BPM) 9.Able to comprehend and willing to sign an ICF and to abide by the study restrictions Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 4
Exclusion criteria
Exclusion criteria: All parts and all groups (control healthy volunteers and hepatic impairment) 1.History of an organ transplant, including a remote history of bone marrow transplant. 2.History of febrile illness within 7 days prior to the first dose of study drug or participants with evidence of active infection. 3.Use of any oral glucocorticoids at any dose within 30 days prior to Screening and until study completion . 4.Have previously completed or withdrawn from a study investigating GB1211 and have previously received the investigational product. (applicable for Part 1 and Part 3 only) 5.Participant who, in the opinion of the Investigator (or Designee), should not participate in this study. 6.Vulnerable/institutionalised patients. 7.Patients related to Principal Investigator (PI)/site staff. 8.If female, the participant is of child-bearing potential. 9.Participation in a clinical study involving administration of an investigational agent e.g. new chemical entity or a biological product in the past 90 days (or 5 multiples of half-life, whichever is longer) prior to dosing. 10.Medical history of cardiac disease and/or clinically significant ECG abnormalities. An abnormal ECG is defined as PR > 220 msec, QRS complex >120 msec, QTcF > 450 msec (males) and > 470msec (females), or any other morphological changes, other than nonspecific T-wave changes. 11.Donation or loss of = 400 mL blood or plasma less than 4 weeks prior to screening, or longer if required by local regulations. 12.Positive HIV test. 13.Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) and until study completion. 14.Use of any medications/products that may inhibit biliary excretion, e.g. bile salt chelators, mycophenolic acid, warfarin, and digoxin, within 30 days prior to Screening and until study completion. 15.Use of any medications/products that may inhibit renal excretion; e.g. cimetidine, pyrimethamine, dolutegravir, probenecid, within 30 days prior to Screening and until study completion. 16.Use of any medications/products that are known inhibitors of P-gp (e.g. clarithromycin, fostamatinib, quinidine, quinine) and inducers of P-gp (e.g. carbmazepine, rifampin, St. John’s wort) within 30 days prior to Screening and until study completion. Additional exclusion criteria for matched healthy control subjects: 17.Use of any prescription or non-prescription medication (OTC), herbal medication, dietary supplements or vitamins during 30 days prior to dosing.Acetaminophen is acceptable. 18.History or presence of liver disease or liver injury as indicated by an abnormal liver function profile such as AST, ALT, alkaline phosphate, or serum bilirubin 19.A positive Hepatitis C test or a positive Hepatitis B surface antigen (HBsAg) 20.Estimated glomerular filtration rate (eGFR) < 80 mL/[min*1.73 m² (estimated using the Modification of Diet in Renal Disease [MDRD] equation) at Screening Additional exclusion criteria for hepatic impaired subjects: Participants meeting any of the following exclusion criteria are not to be enrolled in the study/randomised to treatment: 21.History of any known serious disease (such as cancer, except skin basal cell carcinomas, major infection, clinically significant gastrointestinal disorder, major autoimmune disease) or other disease which in the Investigator’s opinion would exclude the patient from the study 22.Estimated glomerular filtration rate (eGFR) < 40 mL/[min*1.73 m²] (estimated using the MDRD equation) at
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary objective (Part 1, 2 and 3): To assess the effect of hepatic impairment on the safety, tolerability and pharmacokinetics of GB1211 in participants with moderate or severe hepatic impairment. ;Secondary Objective: Secondary objectives (Part 2): To assess the effect of GB1211 on liver and spleen stiffness and on hepatic function in participants with moderate hepatic impairment ;Primary end point(s): •AEs, SAEs, clinical laboratory investigations, haematology and urinalysis, vital signs, physical examination, and ECGs; •Plasma concentrations and pharmacokinetic parameters of unbound and total GB1211 •Urine concentrations and pharmacokinetic parameters of GB1211 ;Timepoint(s) of evaluation of this end point: Please refer to the schedule of assessments within the protocol. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Applicable only to Part 2 of the study: •Maximum liver function capacity assessment as measured by liver maximum capacity (LiMAx) test (a dynamic liver function test based on the metabolism of 13C-methacetin by the liver-specific cytochrome P450 1A2 system); •FibroScan: Liver and spleen stiffness measured in kPa by transient elastography ;Timepoint(s) of evaluation of this end point: Please refer to the schedule of assessments within the protocol. | — |
Countries
Bulgaria
Contacts
Public ContactChief Medical Officer
Galecto Biotech AB
Outcome results
None listed